Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References We expect Q4 to reflect continuation of return to normal healthcare systems. Q1/Q2 impacted by PY COVID-19 stocking/destocking Group quarterly growth vs. PY %pts, constant currency Sales -2 9 Mid 5 single digit Low to Mid single digit Core Operating Income 13 High 9 single digit Mid single digit -8 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY 42 Investor Relations | Q3 2021 Results Actual Illustrative 1 NOVARTIS | Reimagining Medicine

View entire presentation